×

Dependence in a national sample of Aboriginal and Torres Strait Islander daily smokers

In 1988, the United States Surgeon General concluded that nicotine is the drug in tobacco that causes dependence on smoking.1 The nicotine that is delivered to the brain when smoking interacts with the habits and sensory stimuli associated with smoking to reinforce the behaviour.2 Genetic factors also influence the biological processes of nicotine delivery, metabolism and dependence.2

Clinicians and scientists have sought indicators to predict the success or failure of quit attempts, beyond indicators of motivation. The best such measure is the Heaviness of Smoking Index (HSI),3 or at least one of its two component items: cigarettes per day (CPD) and the time to first cigarette (TTFC) after waking.4,5 These two items are a subset of the six items in the Fagerström Test for Nicotine Dependence.6 There is also evidence that strong cravings (both before and after quitting) and shorter periods of abstinence on past attempts may independently predict failure of quit attempts.79 Identifying smokers who are most likely to have difficulty quitting is important in determining who might benefit from medications to assist cessation.

The age-standardised prevalence of smoking is 2.6 times higher among Aboriginal and Torres Strait Islander people as among other Australians.10 While both smoking prevalence and smoking intensity (based on self-reported CPD) are falling among the Aboriginal and Torres Strait Islander population, measures of dependence may differently predict which smokers will have the most difficulty quitting in this high-prevalence population where smoking is more normalised.10,11 Two small research reports have suggested that over-reliance on strategies that use stop-smoking medications may not be appropriate in this population, as nicotine dependence may be lower than in other populations.12,13 One of these studies found only low per capita consumption of cigarettes in remote Aboriginal communities,12 and the other found that only a small proportion of a sample of pregnant Aboriginal and Torres Strait Islander women who smoked were highly dependent.13

Here, we use a large national study of Aboriginal and Torres Strait Islander smokers to examine different indicators of dependence in this population and their association with sustained quit attempts, and to make comparisons with a national sample of Australian smokers.

Methods

The Talking About The Smokes (TATS) project surveyed 1392 Aboriginal and Torres Strait Islander daily smokers using a quota sampling design in the communities served by 34 Aboriginal community-controlled health services (ACCHSs) and one community in the Torres Strait, and has been described elsewhere.14,15 Briefly, the 35 sites were selected based on the distribution of the Aboriginal and Torres Strait Islander population by state or territory and remoteness. In 30 sites, we aimed to interview 50 smokers or ex-smokers who had quit ≤ 12 months before, and 25 non-smokers, with equal numbers of women and men and of those aged 18–34 and ≥ 35 years. In four major-city sites and the Torres Strait community, the sample sizes were doubled. People were excluded if they were aged less than 18 years, not usual residents of the area, staff of the ACCHS, or deemed unable to complete the survey. In each site, different locally determined methods were used to collect a representative, although not random, sample.

Baseline data were collected from April 2012 to October 2013. Interviews were conducted face to face by trained interviewers, almost all of whom were members of the local Aboriginal and Torres Strait Islander community. The survey was completed on a computer tablet and took 30–60 minutes. The baseline sample closely matched the national distribution of age, sex, jurisdiction, remoteness, quit attempts in the past year and number of daily cigarettes smoked reported in the 2008 National Aboriginal and Torres Strait Islander Social Survey (NATSISS). However, there were inconsistent differences in some socioeconomic indicators: our sample had higher proportions of unemployed people, but also higher proportions who had completed Year 12 and who lived in more advantaged areas.14

The TATS project is part of the International Tobacco Control Policy Evaluation Project (ITC Project) collaboration. Interview questions were closely based on those in ITC Project surveys, especially the Australian surveys.16 TATS project results were compared with those for 1010 daily smokers surveyed in Wave 8.5 of the Australian ITC Project between September 2011 and February 2012. That survey was completed by random digit telephone dialling or on the internet, and included smokers contacted for the first time and those who were recontacted after completing surveys in previous waves.

We asked questions about daily smokers’ usual smoking behaviour and variations in tobacco consumption, how easy it would be to not smoke, difficulties during their most recent quit attempt (eg, strong cravings, being around others who smoke), the duration of their longest quit attempt (to assess if any attempt had been sustained for at least 1 month) and sociodemographic factors. The questions are described in detail in Appendix 1.

The HSI was coded 0 to 6 based on the sum of the responses to the two questions about CPD and TTFC. These items were each coded as 0 (0–10 CPD; TTFC, ≥ 61 min), 1 (11–20 CPD; TTFC, 31–60 min), 2 (21–30 CPD; TTFC, 6–30 min) or 3 (≥ 31 CPD; TTFC, ≤ 5 min).3 We categorised HSI as low (0–1), moderate (2–3) or high (4–6).17,18 We also assessed the three criteria for dependence given in the Royal Australian College of General Practitioners (RACGP) cessation guidelines: TTFC ≤ 30 min, > 10 CPD, and withdrawal symptoms on previous quit attempts (defined in our sample as strong cravings during the most recent quit attempt).2

The project was approved by three Aboriginal human research ethics committees (HRECs) and two HRECs with Aboriginal subcommittees: Aboriginal Health & Medical Research Council Ethics Committee, Sydney; Aboriginal Health Research Ethics Committee, Adelaide; Central Australian HREC, Alice Springs; HREC for the Northern Territory Department of Health and Menzies School of Health Research, Darwin; and the Western Australian Aboriginal Health Ethics Committee, Perth.

Statistical analyses

We calculated the percentages and frequencies of responses to the TATS project questions, but did not include confidence intervals for these as it is not considered statistically acceptable to estimate sampling error in non-probabilistic samples. Therefore, we could not assess the statistical significance of differences with the Australian ITC Project results. The results for daily smokers in the Australian ITC Project were directly standardised to the distribution of age and sex of Aboriginal and Torres Strait Islander smokers reported in the 2008 NATSISS.

Within the TATS project sample, we assessed the association between sociodemographic variables and HSI using χ2 tests adjusted for the sampling design, using the 35 sites as clusters and the age–sex quotas as strata in Stata 13 (StataCorp) survey [SVY] commands.19 We assessed the association between indicators of dependence and sustained quit attempts using simple logistic regression, with confidence intervals adjusted for the sampling design and P values calculated for each variable using adjusted Wald tests.

Reported percentages and frequencies exclude those refusing to answer, answering “don’t know”, or for whom the question was not applicable (eg, questions about the most recent quit attempt excluded those who had not made an attempt in the past 5 years). Less than 2% of daily smokers answered “don’t know” or refused to answer each of the questions analysed here, except that 18 smokers (2.0%) answered “don’t know” to the question about difficulty in saying no when offered a cigarette during their most recent quit attempt, and 32 (2.3%) refused to answer the question about being unable to afford to buy cigarettes.

Results

There was little difference in the mean HSI scores for daily smokers in the TATS project compared with those in the Australian ITC Project (2.62 v 2.64; 95% CI, 2.45–2.83), but the TATS sample had fewer low and high scores and more moderate scores (Box 1). A higher proportion of smokers in the TATS project smoked 10 or fewer cigarettes per day (40% v 33.4%), but more also smoked their first cigarette within 30 minutes of waking (75% v 64.6%; 95% CI, 58.8%–70.0%). Lower proportions of Aboriginal and Torres Strait Islander smokers reported having strong urges to smoke at least several times a day (51% v 60.7%) or that it would be very hard to quit (39% v 47.9%).

Within the TATS sample, older smokers were more likely to have higher HSI scores, as were smokers who were not in the labour force, those with less education, those from both the most and least disadvantaged areas, and Aboriginal smokers compared with Torres Strait Islander smokers (Box 2).

Box 3 presents the results for questions that were only asked in the TATS project. Nearly half the smokers (47%) reported finding it very or extremely hard to go without smoking for a whole day, and most reported experiencing difficulties during their most recent quit attempt. A quarter (24%) of daily smokers had all three of the RACGP indicators of dependence.

Among the 61% of smokers in the TATS sample (833/1371) who had made a quit attempt in the past 5 years, all the indicators of dependence, except CPD and strong urges, were associated with being less likely to have made a sustained quit attempt of at least 1 month (Box 4). The indicators with the strongest negative associations with making a sustained quit attempt were the smokers’ assessments of how hard it would be to quit and their difficulties during the most recent quit attempt. Although the HSI and the RACGP criteria of dependence were negatively predictive of making a sustained quit attempt, CPD — one of their component measures — was not.

Nearly half the daily smokers in the TATS sample (45%, 606/1354) reported being unable to buy cigarettes for at least a few days in each fortnight before pay day, and 23% (314/1354) less often, while for 32% (435/1354) this was never a problem. When smokers were unable to buy them, 37% (342/916) reported they were often or very often given cigarettes, and 50% (460/916) were sometimes given them. As a result, 27% (245/911) said they smoked the same amount as usual when unable to buy cigarettes, while 50% (456/911) smoked a bit less and only 23% (210/911) smoked a lot less or not at all.

Compared with Australian smokers in the ITC Project, fewer Aboriginal and Torres Strait Islander smokers in the TATS project reported that the amount they smoked varied from day to day (42% [580/1392] v 58.5% [95% CI, 53.1%–63.7%]), but more reported that spending money on cigarettes left them with insufficient money for food or other essentials (23% [321/1378] v 12.9% [95% CI, 8.7%–18.6%]).

The Aboriginal and Torres Strait Islander smokers whose smoking led to insufficient money for essentials were less likely to have made sustained attempts to quit (odds ratio [OR], 0.70; 95% CI, 0.37–0.71; P < 0.001). Smokers who were never unable to afford cigarettes were less likely to have made a sustained quit attempt than those who were sometimes unable to buy them (OR, 0.51; 95% CI, 0.37–0.71; < 0.001). Those who said they smoked about the same as usual when they were unable to buy cigarettes were also less likely to have made a sustained quit attempt, compared with those who at such times smoked a lot less or not at all (OR, 0.61; 95% CI, 0.41–0.91; P = 0.01).

Discussion

We found mixed relationships between indicators for dependence and sustained quit attempts in our sample of Aboriginal and Torres Strait Islander smokers. Based on CPD, frequency of strong urges to smoke and perceptions of how hard it would be to quit, dependence in this population appeared lower than among all Australian smokers. In contrast, our sample had a shorter TTFC. Nevertheless, the associations we found between dependence, as measured by the HSI, and being older and socially disadvantaged were similar to those in previous cross-sectional Australian ITC Project research.20

Previous research suggests TTFC is a more useful measure of dependence and a better predictor of successful quitting than CPD, although both are predictive and may contribute independently.4,5,21,22 Consistent with this, we found that longer TTFC was associated with having made a sustained quit attempt, while CPD was not. However, we also found no association for the frequency of strong urges while still smoking, which has been shown to be associated with successful quitting in longitudinal research, performing better than the Fagerström Test for Nicotine Dependence or its components, HSI, TTFC or CPD.7,8 These findings question the utility of existing indicators of dependence to predict successful quitting in Aboriginal and Torres Strait Islander smokers.

Aboriginal and Torres Strait Islander smokers’ perceptions of greater ease in quitting (quitting self-efficacy) may be falsely optimistic, perhaps reflecting less experience of unsuccessful quit attempts.23 In 2012–2013, only 37% of Aboriginal and Torres Strait Islander adults who had ever smoked had successfully quit, compared with 63% of other Australians.10 Some of the cross-sectional association we found between quitting self-efficacy and sustained quit attempts is likely to be in the reverse direction, with those who have not been able to sustain quit attempts understandably reporting that quitting will be harder. However, in other longitudinal research of the ITC Project, quitting self-efficacy has been associated with preventing relapses, both before and after a month.7 Nevertheless, we can take advantage of this optimism to encourage quit attempts.

Most Aboriginal and Torres Strait Islander smokers reported withdrawal symptoms (cravings) and situational difficulties during their most recent quit attempt, which have been described in more detail in previous qualitative research.24 It is notable that questions about the most recent quit attempt were consistently stronger predictors of being unable to sustain quit attempts than were traditional measures of dependence based on typical daily smoking patterns. Our results are consistent with more detailed recent research in other settings, which suggested that the components of the HSI are only predictive of early relapses in the first weeks of a quit attempt, whereas cravings and situational cues (such as the number of close friends who smoke) are important after 1 month.7,25

Current clinical guidelines recommend that clinicians ask smokers not only about CPD and TTFC, but also about their past unsuccessful quit attempts.26,27 Beyond emphasising the utility of the existing question about difficulties experienced during past attempts, we recommend waiting for further research on how the different measures prospectively predict quitting success before suggesting changes to the guidelines for Aboriginal and Torres Strait Islander smokers.

It is possible that estimates of CPD might be less accurate among Aboriginal and Torres Strait Islander smokers, where the relationship between purchase and consumption is more complicated because sharing and being unable to buy cigarettes are common. Two small studies of Aboriginal and Torres Strait Islander people showed that self-reported CPD is associated with urinary cotinine levels, but did not discuss whether the association was similar to that in other populations.28,29 However, we found that Aboriginal and Torres Strait Islander smokers were less likely than all Australian smokers to report variation in the number of cigarettes smoked each day, so it is difficult to suggest that such day-to-day variations are the reason for CPD being less useful in this setting. Those who managed to maintain usual consumption levels when they were unable to buy cigarettes were less likely to have sustained a quit attempt than those who smoked less at these times. Sharing of cigarettes therefore seems to increase in response to the inability to buy cigarettes among more dependent smokers, as has been reported elsewhere in response to pay cycles and the increased cost of cigarettes after tobacco excise rises.24,30

Strengths and limitations

The main strength of our study is its large national sample of Aboriginal and Torres Strait Islander smokers, providing detailed information about dependence directly from a population with a high prevalence of smoking. However, it is a non-random, albeit broadly representative, sample and caution is needed in making comparisons with the Australian ITC Project sample.

The cross-sectional associations we found warrant confirmation from future longitudinal analyses. There may have been some reverse causation, with past experiences of sustaining or not sustaining quit attempts influencing answers to the questions about dependence. Further, sustained attempts may have occurred years earlier, and the smokers’ dependence may have since changed. The use of past sustained quit attempts as an outcome necessarily meant excluding those who had not made any attempts. Predicting future quitting in this subgroup will be important but cannot include measures based on non-existent past attempts.

Our self-reported data are probably limited by incomplete recall of past quit attempts, and both forgetting and misremembering of symptoms. The effect of most of these biases will be to weaken reported associations, leading to greater confidence in the significant associations but requiring caution in the implications of findings of no association. For example, the lack of association of strong urges to smoke with sustained quitting found here, in contrast to other research, requires further exploration.8 More Aboriginal smokers than other Australian smokers use roll-your-own cigarettes, which may have caused greater misclassification bias of estimates of CPD.31 Future longitudinal analyses of the predictive association of these dependence measures with relapses and successful quitting should also control for the moderating effect of stop-smoking medication, which we were not able to do.25

1 Comparison of indicators of nicotine dependence among Aboriginal and Torres Strait Islander daily smokers and those in the Australian population*

Indicator of dependence

Talking About The Smokes project, % (frequency)

Australian ITC Project,
% (95% CI)


Cigarettes per day

   

1–10

40% (547)

33.4% (27.9%–39.3%)

11–20

39% (528)

42.2% (36.8%–47.7%)

21–30

18% (242)

18.5% (14.7%–22.9%)

≥ 31

4% (54)

6.0% (3.7%–9.6%)

Time to first cigarette

   

More than 60 minutes

9% (125)

16.1% (11.9%–21.3%)

31–60 minutes

16% (220)

19.4% (15.3%–24.2%)

6–30 minutes

64% (884)

46.7% (41.2%–52.3%)

5 minutes or less

11% (145)

17.9% (13.6%–23.2%)

Heaviness of Smoking Index (HSI) score

   

Low (0–1)

17% (234)

24.5% (19.5%–30.3%)

Moderate (2–3)

59% (796)

44.6% (39.2%–50.1%)

Heavy (4–6)

24% (328)

30.9% (25.8%–36.5%)

How often do you get strong urges to smoke?

   

Never or less than daily

21% (291)

12.4% (9.0%–16.9%)

Daily

27% (375)

26.9% (21.9%–32.5%)

Several times a day or more often

51% (706)

60.7% (54.9%–66.2%)

How easy or hard would it be for you to quit?

   

Very or somewhat easy

17% (234)

10.4% (6.9%–15.4%)

Neither easy nor hard

11% (156)

7.9% (5.0%–12.2%)

A little bit hard

32% (439)

33.7% (28.8%–39.0%)

Very hard

39% (537)

47.9% (42.3%–53.6%)


ITC Project = International Tobacco Control Policy Evaluation Project. * Percentages and frequencies exclude refused responses and “don’t know” responses. † Results are for Aboriginal and Torres Strait Islander daily smokers (n = 1392) in the baseline sample of the Talking About The Smokes project (April 2012 – October 2013). ‡ Results are for daily smokers (n = 1010) in the Australian population from Wave 8.5 of the Australian ITC Project (September 2011 – February 2012) and were age- and sex-standardised to smokers in the 2008 National Aboriginal and Torres Strait Islander Social Survey.

2 Heaviness of Smoking Index among Aboriginal and Torres Strait Islander daily smokers, by sociodemographic factors (n = 1392)*

 

Heaviness of Smoking Index score


 

Characteristic

Low, % (frequency)

Moderate, % (frequency)

High, % (frequency)

P


Total daily smokers

17% (234)

59% (796)

24% (328)

 

Age (years)

     

< 0.001

18–24

22% (60)

68% (187)

11% (29)

 

25–34

21% (76)

57% (209)

23% (84)

 

35–44

14% (45)

58% (186)

28% (92)

 

45–54

16% (37)

56% (132)

28% (67)

 

≥ 55

10% (16)

53% (82)

36% (56)

 

Sex

     

0.12

Female

19% (134)

59% (417)

22% (153)

 

Male

15% (100)

58% (379)

27% (175)

 

Indigenous status

     

0.027

Aboriginal

16% (195)

59% (717)

25% (297)

 

Torres Strait Islander or both

26% (39)

53% (79)

21% (31)

 

Labour force status

     

< 0.001

Employed

21% (101)

58% (274)

21% (97)

 

Unemployed

18% (82)

63% (293)

19% (89)

 

Not in labour force

12% (51)

54% (227)

34% (142)

 

Highest education attained

     

0.036

Less than Year 12

14% (101)

59% (411)

27% (188)

 

Finished Year 12

19% (68)

58% (204)

23% (80)

 

Post-school qualification

22% (63)

59% (172)

20% (57)

 

Treated unfairly because Indigenous in past year

     

0.72

Never

18% (106)

57% (335)

25% (145)

 

At least some of the time

17% (124)

59% (439)

24% (176)

 

Remoteness

     

0.34

Major cities

15% (52)

60% (214)

25% (88)

 

Inner and outer regional

19% (137)

59% (420)

22% (158)

 

Remote and very remote

16% (45)

56% (162)

28% (82)

 

Area-level disadvantage

     

0.027

1st quintile (most disadvantaged)

16% (83)

57% (290)

27% (137)

 

2nd and 3rd quintiles

21% (121)

59% (342)

21% (121)

 

4th and 5th quintiles

11% (30)

62% (164)

27% (70)

 

* Percentages and frequencies exclude those answering “don’t know” or refusing to answer. † P values were calculated using the χ2 test adjusted for sampling design.

3 Other indicators of nicotine dependence and difficulties during the most recent quit attempt among Aboriginal and Torres Strait Islander daily smokers

Indicator of dependence

Daily smokers, % (frequency)*


All daily smokers (n)

1392

RACGP criteria for dependence

 

None

12% (162)

One

24% (334)

Two

41% (564)

All three

24% (327)

How hard is it to go without smoking for a whole day?

 

Not at all or somewhat hard

47% (654)

Very or extremely hard

47% (657)

Not sure or never tried

6% (79)

If tried to quit in the past 5 years (n)

884

During last quit attempt

 

Had strong cravings

70% (591)

Hard to be around smokers

72% (621)

Hard to say no when offered a smoke

67% (572)

Missed the time out you get when having a smoke

51% (430)


RACGP = Royal Australian College of General Practitioners. * Percentages and frequencies exclude those answering “don’t know” or refusing to answer. † Time to first cigarette ≤ 30 min, > 10 cigarettes per day, and withdrawal symptoms on previous quit attempts (strong cravings during most recent quit attempt).

4 Association of indicators of dependence with sustaining a quit attempt for at least 1 month in a national sample of Aboriginal and Torres Strait Islander daily smokers*

Indicator of dependence

Sustained quit attempt,
% (frequency)

Odds ratio (95% CI)

P§


Total

47% (388)

   

Heaviness of Smoking Index score

   

0.046

Low (0–1)

50% (71)

1.0

 

Moderate (2–3)

48% (238)

0.91 (0.66–1.26)

 

Heavy (4–6)

38% (68)

0.60 (0.39–0.91)

 

RACGP criteria for dependence

   

0.001

None

54% (38)

1.0

 

One

57% (92)

1.12 (0.60–2.09)

 

Two

47% (133)

0.73 (0.43–1.24)

 

All three

39% (124)

0.55 (0.33–0.90)

 

Cigarettes per day

   

0.19

1–10

47% (153)

1.0

 

11–20

48% (163)

1.02 (0.75–1.38)

 

21–30

45% (57)

0.89 (0.58–1.37)

 

≥ 31

27% (9)

0.42 (0.18–0.94)

 

Time to first cigarette

   

0.024

More than 60 minutes

53% (43)

1.0

 

31–60 minutes

55% (73)

1.08 (0.57–2.03)

 

6–30 minutes

45% (235)

0.72 (0.45–1.13)

 

5 minutes or less

36% (31)

0.51 (0.27–0.94)

 

How often do you get strong urges to smoke?

   

0.49

Never or less than daily

49% (90)

1.0

 

Daily

47% (109)

0.91 (0.61–1.38)

 

Several times a day or more often

45% (184)

0.82 (0.58–1.17)

 

How hard is it to go without smoking for a whole day?

   

0.01

Not at all or somewhat hard

51% (219)

1.0

 

Very or extremely hard

42% (159)

0.69 (0.52–0.92)

 

Not sure or never tried

33% (9)

0.47 (0.22–1.05)

 

How easy or hard would it be for you to quit?

   

< 0.001

Very or somewhat easy

61% (94)

1.0

 

Neither easy nor hard

53% (46)

0.72 (0.42–1.25)

 

A little bit hard

46% (125)

0.53 (0.36–0.78)

 

Very hard

38% (120)

0.39 (0.27–0.56)

 

During most recent quit attempt

     

Did you get strong cravings?

   

< 0.001

No

59% (149)

1.0

 

Yes

42% (236)

0.49 (0.37–0.66)

 

Was it hard to be around smokers?

   

< 0.001

No

59% (133)

1.0

 

Yes

42% (252)

0.51 (0.38–0.69)

 

Was it hard to say no when offered a smoke?

   

< 0.001

No

58% (154)

1.0

 

Yes

41% (225)

0.50 (0.35–0.70)

 

Did you miss the time out you get when having a smoke?

   

0.03

No

51% (197)

1.0

 

Yes

44% (179)

0.74 (0.56–0.98)

 

RACGP = Royal Australian College of General Practitioners. * Results are based on daily smokers in the baseline sample of the Talking About The Smokes project who had made at least one quit attempt in the past 5 years (n = 833). † Percentages and frequencies exclude those answering “don’t know” or refusing to answer. ‡ Odds ratios calculated using simple logistic regression adjusted for the sampling design. § P values for the entire variable, using adjusted Wald tests.

The ghosts of Budgets past

While listening to the Secretary of the Department of Health in the Health Budget lock-up in Canberra on Tuesday night, I was more than a little surprised that the sales pitch to Australia’s health leaders was that the centrepiece of the 2015 Health Budget was the Review of the Medicare Benefits Schedule (MBS) – a measure that had been announced some months earlier with supposedly no Budget revenue implications.

I was even more surprised when the Secretary inferred that the MBS Review would deliver further considerable savings to the Government. Health Minister, Susan Ley, has since clarified that this was not the Government’s intention.

It is not purely about a savings measure, it is about making sure that we have a modern MBS that actually reflects modern medical practice, and it actually maintains access for patient services.

Nevertheless, given the damage caused to the Government from last year’s Budget co-payment proposals and public hospital funding cuts – misguided measures that brought misery to the Government for the best part of a year – the general expectation was that the Government would play some strong suits in health policy.

That was not the case. Instead, we saw a range of modest (but welcome) announcements that remain completely overshadowed by the lingering negative effects of the Medicare patient rebate freeze and public hospital funding cuts – the ghosts of Budgets past.

The Budget unfortunately does not go anywhere near addressing the concerns of the AMA from last year’s Budget.

There is no indication that the public hospital cuts are going to be restored. Nor is there any indication about the required changes for the indexation freeze that we are seeing for GP and specialist patient rebates.

People need to remember that the indexation freeze is a freeze for the patient’s rebate. It is not about the doctor’s income. It is actually about the patient’s rebate and their access to services. There is no indication that those freezes are going to be lifted any earlier than 2018.

There have also been cuts of nearly $150 million taken out of general practice from changes to the child health checks, apparently because of ‘duplication’. It is very unclear where the so-called duplication occurs.  Such a change would have been better dealt with as part of the MBS Review, rather than as a hastily conceived Budget saving measure.

There is also a lack of clarity around some of the announced cuts. There was a mystery package of $1.7 billion in cuts that was claimed to cover child health assessments, a number of dental programs, and ‘flexible funds’ for NGOs in the health sector. A big number, but little detail. The end result is a number of small organisations that do very good work looking after vulnerable people left wondering about their funding and their future.

The focus should have been on positives.

The AMA welcomed a range of other measures, including:

  • e-health changes, including the myHealth Record, particularly the opt-out component;
  • mental health plan;
  • support for the National Critical Care and Trauma Response Centre;
  • funding for Aboriginal Community Controlled health organisations;
  • organ donation programs; and
  • the Ice Action strategy.

The AMA has been invited by the Minister for briefing and clarification of issues such as Indigenous health program funding, after hours care, and preventive health.

Public and preventive health programs under cloud

The future of important public and preventive health and support programs for Alzheimer’s, palliative care, alcohol and addiction, rural and Indigenous health are under a cloud after the Federal Government announced almost $1 billion of cuts from health programs.

In a decision that has thrown doubts over the funding of organisations including Alzheimer’s Australia, Palliative Care Australia and the Foundation for Alcohol Research and Education, the Government said it would achieve savings of $962.8 million over the next five years by “rationalising and streamlining funding across a range of Health programs”, including so-called Health Department Flexible Funds, dental workforce programs, preventive health research, GP Super Clinics  and several other sources.

AMA President Associate Professor Brian Owler the lack of detail around the savings was concerning.

“There is a lot of uncertainty in Canberra and around the country at the moment as to whether those important programs, those important organisations, such as Palliative Care Australia, Alzheimer’s Australia, the Foundation for Alcohol Research and Education, and many other non-government organisations, are going to be continued to be funded,” A/Professor Owler said. “Rather than announcing that these cuts of almost $1 billion are going to be made to those flexible funds, and leaving it up in the air for these organisations, we need to see certainty around where those cuts are going to be made, how they are going to be applied, so that these organisations can not only plan for their future but also continue their very important work.”

In addition, the Government has tagged the Health Department for an extra $113.1 million of savings in the next five years as part of its Smaller Government initiative.

It said this would be achieved by measures including consolidating the Therapeutic Goods Administration’s corporate and legal services into the Health Department, axing the National Lead Clinicians Group, replacing IT contractors by recruiting full-time staff and “ceasing activities that mirror the work of specialist agencies”, such as the Independent Hospital Pricing Authority, the National Blood Authority, and the Australian Institute of Health and Welfare.

Adrian Rollins

 

 

Child protection Australia 2013–14

This report contains comprehensive information on state and territory child protection and support services in 2013-14, and the characteristics of Australian children within the child protection system. This report shows that: – around 143,000 children, a rate of 27.2 per 1,000 children, received child protection services (investigation, care and protection order and/or in out-of-home care); – three-quarters (73%) of these children had previously been the subject of an investigation, care and protection order and/or out-of-home care placement; – Aboriginal and Torres Strait Islander children were 7 times as likely as non-Indigenous children to be receiving child protection services.

Statin-associated myotoxicity in an incarcerated Indigenous youth — the perfect storm

Clinical record

A previously healthy 18-year-old dark-skinned Indigenous man was incarcerated in a juvenile detention centre in New South Wales for 3.5 years from 2010 to 2013. Juvenile detention limits outdoor activity and, consequently, exposure to sunlight. Young people are confined indoors for schooling and other programs, with additional periods of cell lockdowns to accommodate detainee movements and staff handovers. Periods outdoors involve bursts of strenuous physical activity, mostly team sports or swimming. Further, detention centre policy requires young people to wear T-shirts and hats, and to use sun protection factor 30+ sunscreen when outdoors.

On entering custody, the patient’s weight was 65 kg, with a healthy body mass index (BMI) of 21 kg/m2 (reference interval [RI], 18.5–24.9 kg/m2). Full blood count, urea, electrolyte and creatinine levels and liver function test results were normal, and a blood-borne virus screen returned a negative result. He had a strong family history of type 2 diabetes in his mother and maternal grandmother, and, reportedly, of hypercholesterolaemia and early cardiovascular death in his father and paternal grandfather.

Seven months after incarceration, the man developed auditory and visual hallucinations and was noted to be withdrawn and depressed, with long periods spent resting in his cell owing to fatigue. He was commenced on the antipsychotic quetiapine 150 mg at night and the antidepressant fluoxetine 20 mg in the morning. At commencement of these medications, his weight was 89 kg (BMI, 29 kg/m2). Baseline pathology tests were not repeated at this time.

Six months after commencement of psychotropic medications, his weight had increased a further 25 kg to 114 kg and he was morbidly obese (BMI, 36 kg/m2), with phenotypes of metabolic syndrome including central obesity (waist circumference, 108 cm [RI, < 94 cm]), hyperlipidaemia (total cholesterol, 7.8 mmol/L [RI, < 5.5 mmol/L]; low-density lipoprotein cholesterol, 4.9 mmol/L [RI, < 4.0 mmol/L]; high-density lipoprotein cholesterol, 0.8 mmol/L [RI, > 1.0 mmol/L]), elevated triglyceride level (2.28 mmol/L [RI, < 2.0 mmol/L]), and fatty liver disease (γ-glutamyl transferase, 83 U/L [RI, 0–60 U/L]; alkaline phosphatase, 208 U/L [RI, 30–110 U/L]; alanine transaminase, 72 U/L [RI, 0–55 U/L]; aspartate transaminase, 46 U/L [RI, 0–45 U/L]) (Figure). Blood pressure and thyroid-stimulating hormone levels were within normal limits. With concerns about his obesity and metabolic derangements, quetiapine was ceased. He received counselling for dietary restriction (portion control, low saturated fat diet, reduction of energy-dense snacks) and, in particular, was encouraged to avoid the additional bread, butter and sugary drinks that are available to supplement meals. Increased physical activity was encouraged. An off-label trial of metformin was commenced, given the evidence for weight benefits in antipsychotic recipients,1 and increased to 1 g twice daily over the following 4 weeks.

Three months later, the patient’s fasting lipid levels remained similarly elevated despite lifestyle changes, and he agreed to trial atorvastatin 10 mg daily. He was also permitted to take recreational leave from the centre and commenced thrice-weekly training with the local football club.

Three weeks after commencing atorvastatin, the patient complained of worsening fatigue but denied having muscle tenderness, myalgia or cramping. Creatine kinase (CK) levels were normal at atorvastatin commencement, but had risen to 350 U/L (RI, < 170 U/L). Atorvastatin dosage was reduced to 5 mg in the morning, metformin was continued and fluoxetine was ceased.

Serial changes in the patient’s CK levels are shown in the Figure. Five weeks after atorvastatin commencement, lipid levels had improved but CK levels continued to rise and all medications were ceased. There were concerns regarding rhabdomyolysis, but urinalysis results, estimated glomerular filtration rate and renal function remained normal. His physical symptoms remained unchanged. The patient was encouraged to rest and drink plenty of water. He continued to play competition football. CK levels continued to rise, peaking at 3042 U/L.

Serum 25-hydroxyvitamin D levels were found to be low, and he was treated with cholecalciferol (vitamin D3) 1000 IU daily, increasing temporarily to 4000 IU daily after endocrinologist consultation. Serial CK and 25-hydroxyvitamin D levels showed slow improvement initially, with substantial improvements contemporaneous with aggressive vitamin D supplementation (Figure). The patient continued with lifestyle strategies and (in concert with cessation of psychotropic medications) lost 10 kg in weight, but lipid levels remained elevated. Fluoxetine was recommenced by the treating psychiatrist at 20 months because of concerns regarding the patient’s mood.

At the conclusion of his sentence, the patient was released from custody and referred to the local Aboriginal Medical Service for continuing management of his hypercholesterolaemia, myositis, and metabolic and mental health problems.

Indigenous Australians have a reduced life expectancy of up to 20 years compared with non-Indigenous Australians and, by 40 years of age, are 10 times more likely to suffer premature cardiac-related death.2 In recognition of this, the Indigenous Chronic Disease Package (through Closing the Gap initiatives) encourages the use of statins, recommending treatment at lower lipid thresholds.3

There is evidence that Indigenous populations may be at higher risk of statin-related myopathy owing to a higher risk of vitamin D deficiency,4 higher rates of human T-cell lymphotropic virus type 1 infections causing polymyositis5 and, possibly, genetic susceptibility to statin-associated myotoxic effects (the SLCO1B1 gene prevalent in other indigenous populations6). Other risk factors predisposing our patient to statin-related myopathy were his age, strenuous exercise, mild hepatic dysfunction and concomitant use of fluoxetine (a CYP3A4 inhibitor).4,7,8 As CK elevation persisted after atorvastatin cessation, the differential diagnosis was necrotising autoimmune myopathy, previously described in indigenous patients with persistent myopathy.9 The recommencement of fluoxetine at 20 months may also have perpetuated the elevated CK level.

Almost 12 000 people are incarcerated in NSW, with a quarter being Indigenous Australians and at greatest risk of vitamin D deficiency.10 This is the first report of statin-related myopathy in an Indigenous adolescent or an incarcerated person. It is worth noting by other clinicians who work with Indigenous and incarcerated groups that the risk factors for this patient’s “perfect storm” were not unusual — metabolic syndrome, vitamin D deficiency, and use of statins in the context of mental illness and concomitant psychotropic medication use.1,2

This report highlights the need for monitoring of vitamin D levels and supplementation (with an argument for easier access to injectable vitamin D in this group), with pre-statin counselling, particularly for those at high risk of statin-related myopathy — Indigenous Australians, youths, females, and those serving lengthy custodial sentences.

This case also highlights the detrimental effects of antipsychotics on weight and metabolic risk. An international declaration supporting young people with psychosis11 has delineated the obligations of health care providers to prevent weight gain and metabolic complications that contribute to the 25-year shortfall in life expectancy in people with severe mental illness.

In addition to these learning points, there are the obvious problems of the unmet health needs and human tragedy in this vulnerable patient group: a baseline high metabolic risk associated with Aboriginality and family medical history, the constraints of incarceration exacerbating the risk of vitamin D deficiency, and a doubling of weight resulting in rapid-onset obesity secondary to antipsychotic use. Co-prescription of lifestyle interventions at the time of commencing antipsychotic therapy is essential. In addition, metformin has proven efficacy in abrogating weight gain following antipsychotic commencement, with its use encouraged in patients who make clinically significant weight gains.1

Lessons from practice

  • Indigenous Australians, young people and those serving lengthy custodial sentences are at risk of low vitamin D levels and statin-associated myopathy.
  • Aggressive vitamin D supplementation may be required to normalise levels before commencing statin therapy.
  • For all people receiving antipsychotics, lifestyle intervention should be co-prescribed, and weight gain should be monitored and actively prevented.
  • Metformin has proven benefit for weight loss in patients who significantly gain weight on antipsychotic treatment.

Creatine kinase (CK) and other markers according to time and medications.

The AMA a persistent and powerful voice on Indigenous health

By Professor Ian Ring, Professorial Fellow at the Australian Health Services Research Institute, University of Wollongong. Professor Ring has worked with the AMA on Indigenous health issues for more than 20 years.

Nothing exemplifies quite so clearly the AMA’s concern with issues far broader than simply representing the interests of doctors as does its role in Aboriginal health.

That interest is broad in scope, genuine and effective, and dates at least from Dr Brendan Nelson’s term as AMA President in the mid-1990s.

Almost every President since has shared Dr Nelson’s deep, personal and organisational concern and involvement in Aboriginal health, and that involvement is the specific reason I, and no doubt others, joined the AMA many years ago.

That involvement has taken a variety of forms – lobbying, promoting public awareness through the media, preparing and disseminating annual Report Cards on a wide variety of relevant topics, and active engagement with Indigenous organisations and leaders.

Promoting public awareness of issues regarding Aboriginal health has been central to the AMA’s role and purpose, and has taken many forms.

For example, Keith Woollard and I travelled to New Zealand during his term as President (1996-98), notionally to learn more about international experience in improving Indigenous health, but with a secondary aim of drawing the attention of the Australian media. Both aims were achieved. There was substantial Australian press coverage and, equally, we learnt a lot about the linkage of health services with community, cultural, social and economic programs.

Lobbying has taken many forms.

During the late 1990s, when the lack of progress in Aboriginal and Torres Strait Islander health was seen as an international disgrace and symptomatic of a national failure to come to grips with the issues concerning Australia’s Indigenous peoples, the AMA arranged to bring together political, public service and health leaders in an effort to bring about a more effective focus on Indigenous health.

It organised meetings with the-then Prime Minister John Howard and several of his ministers, including Senator Amanda Vanstone, Michael Wooldridge, Tony Abbott and John Herron and Commonwealth Department secretaries. It also met with Aboriginal leaders and organisations, notably the National Aboriginal Community Controlled Health Organisation (NACCHO) and the Australian Indigenous Doctors Association (AIDA) and other leaders of the medical profession.

The AMA’s role became more institutionalised during Dr Kerryn Phelp’s term with the formation of the AMA Indigenous Taskforce, whose membership was drawn from NACCHO,  AIDA, the Indigenous branch of RACGP, Aboriginal health leaders,  AMSA , AMA council members and other AMA members with an active involvement  in Aboriginal health.

Since its inception, the Taskforce has produced annual Indigenous Health Report Cards highlighting issues including infant health, inequality, incarceration, low birth weight, workforce requirements and Indigenous primary health care.

Under the leadership of the current President Associate Professor Brian Owler, the AMA is an active participant in the Close the Gap campaign and lobbies effectively on matters of key importance to Indigenous health, such as patient co-payments.

This is in keeping with the AMA’s well-established role as a persistent, sustained and powerful voice on Indigenous health for at least the past two decades.

During that time, much has changed for the better, particularly as a result of the Close the Gap campaign – although recent cutbacks to funding are a significant concern.

For the future, the development of the Implementation Plan for the National Aboriginal and Torres Strait Island Health Plan will be a priority, including ensuring that it is guided by the voice of Aboriginal people and effectively addresses issues of culture and racism, as well as the practical issues of service models, building service capacity and ensuring an adequate workforce and funding.

 

 

Health at the core of closing the gap

AMA President Associate Professor Brian Owler has warned that governments need to increase their investment in health in order to close the yawning gap in life expectancy and wellbeing between Indigenous people and other Australians.

In a veiled swipe at the Federal Government’s policy focus on school attendance and employment in Indigenous communities, A/Professor Owler told a major international conference on the social determinants of health that too often the importance of wellbeing was overlooked.

“Health is the cornerstone on which education and economics are built,” the AMA President said. “If you can’t go to school because you or your family are sick, truancy officers won’t work. If you can’t hear because of otitis media, you won’t learn. If you miss training opportunities because of depression or ill health, you won’t progress to employment. You can’t hold down a job if you keep having sick days.”

His remarks to a British Medical Association symposium on the role of physicians in addressing the social determinants of health came a month after Prime Minister Tony Abbott admitted that the nation had fallen behind on meeting most of its Closing the Gap targets.

While there has been some improvement in the life expectancy of Aboriginal and Torres Strait Islander people, Indigenous men still on average 10.6 years earlier than other Australian males, and the gap for women is 9.5 years.

In his speech, A/Professor Owler said that in many respects the term ‘social determinants of health’ was misconstrued, because health was in fact a determinant of social and other outcomes.

He said the fact that chronic and non-communicable diseases and other preventable occurrences such as suicide, trauma and injury accounted for a major proportion of the gap in life expectancy underlined the need for greater investment in health care, particularly Aboriginal community controlled health services.

“While those with chronic disease need to be cared for, prevention, particularly in the early part of life, is the key if we are going to see a generational change in health outcomes,” A/Professor Owler said.

He said hard-earned experience showed that health was fundamental to closing the gap, as was the need to work in partnership with Indigenous communities themselves.

“There have been many examples of governments trying to address the social determinants of health – but often they have failed,” he said, referring to policies including building inappropriate housing and taking children from their families.

The AMA President said any attempt to improve Indigenous health needed to acknowledge the fundamental importance for Aboriginal and Torres Strait Islander people of their connection with the land, and understand that in many Aboriginal languages health was a concept of social and emotional wellbeing rather than a physical attribute.

He told the London conference that this was one of reasons why the AMA was a foundation member of the campaign to achieve constitutional recognition for Indigenous Australians.

“Constitutional recognition is a vital step towards making Aboriginal and Torres Strait Islander people feel historically and integrally part of the modern Australian nation,” A/Professor Owler said. “Recognising Indigenous people in the Constitution will improve their self-esteem, their wellbeing, and their physical and mental health.”

Prime Minister Tony Abbott has taken a personal interest in Indigenous affairs, concentrating responsibility for many Indigenous policy areas within the Department of Prime Minister and Cabinet and overseeing the development of the Indigenous Advancement Strategy.

Priorities for the Strategy include improving school attendance, boosting Indigenous employment and improving community safety.

A/Professor Owler said these were all worthy aims, but the Strategy overlooked the central importance of health.

“What is missing from the core of the IAS is a focus on health,” the AMA President said. “Health underpins many of these outcomes. We need to get the balance right and we, the AMA, need to ensure that health is seen as a foundation to these outcomes.”

He said that “spending on health is an investment. Investing in health must underpin our future policies to Close the Gap, and to address what is, for Australia, a prominent blight on our nation”.

Adrian Rollins

 

 

New strains force late start for flu vaccination program

Doctors and patients will for the first time have access to single-dose vaccines covering the four most common flu viruses amid concerns a mutated strain that wreaked havoc in the northern hemisphere could take hold in Australia.

The Therapeutic Goods Administration has approved nine vaccines, including, for the first time, three quadrivalent formulations, as preparations advance for the roll-out of National Seasonal Influenza Immunisation Program from 20 April.

The TGA said the vaccines approved for the program provided coverage for two new strains following expert advice about the prevalence of different types of infections in the last 12 months.

The World Health Organisation and the Australian Influenza Vaccine Committee have recommended that vaccines this year cover one existing and two new strains – the California H1N1-like virus that has been in circulation since 2010, the Switzerland H3N2-like virus and the Phuket 2013-like virus.

In addition, the quadrivalent vaccines, FluQuadri, FluQuadri Junior, and Fluarix Tetra, will cover the Brisbane 2008-like virus.

Drug company Sanofi Pasteur, which manufactures two of the quadrivalent vaccines, said they were well tolerated and provided additional protection because they covered both B strains of the influenza virus as well as the two A strains – compared with trivalent vaccines that covered both A strains but only one B strain.

The national immunisation program, which usually commences in March, had been held back a month as manufacturers have scrambled to produce sufficient stocks of the vaccines.

“The double-strain change has resulted in manufacturing delays due to the time it takes to develop, test and distribute the reagents needed to make the vaccine,” a Health Department spokesperson said. “The commencement of the program is being delayed to ensure sufficient supplies of influenza vaccine are available from at least two suppliers in order to mitigate the risk of administration of bioCSL’s Fluvax to children under five years of age.”

The AMA and other health groups expressed alarm last year over revelations that 43 infants and toddlers were injected with Fluvax in 2013 despite warnings it could trigger fever and convulsions.

The TGA has repeated its advice that Fluvax is not registered for use on children younger than five years, and that it should only be used on children between five and nine years following “careful consideration of potential benefits and risks in the individual child”.

Fluvax will be supplied with prominent warning signs and labels to remind practitioners that it should not be administered to young children.

In a stroke of good fortune, the delay in the vaccination program has coincided with a relatively quiet start to the flu season, with reports that influenza activity has so far been weaker than that experienced at the same time last year.

The Health Department and the TGA said that, despite the delay, they do not expect any flu vaccine shortages, and the Government has committed $4.5 million over the next five years to provide free flu vaccination for Indigenous children aged between six months and five years.

The Government has also renewed the contract of the Australian Sentinel Practices Research Network, based at the University of Adelaide, to undertake national surveillance of flu-like illnesses.

The network, which has been operating for more than a decade, collates information from more than 200 GPs and medical practices across the nation to provide health authorities with an early warning of developing outbreaks. Its information is used in conjunction with data from hospitals.

Adrian Rollins

 

Health at the core of closing the gap

AMA President Associate Professor Brian Owler has warned that governments need to increase their investment in health in order to close the yawning gap in life expectancy and wellbeing between Indigenous people and other Australians.

In a veiled swipe at the Federal Government’s policy focus on school attendance and employment in Indigenous communities, A/Professor Owler told a major international conference on the social determinants of health that too often the importance of wellbeing was overlooked.

“Health is the cornerstone on which education and economics are built,” the AMA President said. “If you can’t go to school because you or your family are sick, truancy officers won’t work. If you can’t hear because of otitis media, you won’t learn. If you miss training opportunities because of depression or ill health, you won’t progress to employment. You can’t hold down a job if you keep having sick days.”

His remarks to a British Medical Association symposium on the role of physicians in addressing the social determinants of health came a month after Prime Minister Tony Abbott admitted that the nation had fallen behind on meeting most of its Closing the Gap targets.

While there has been some improvement in the life expectancy of Aboriginal and Torres Strait Islander people, Indigenous men still on average 10.6 years earlier than other Australian males, and the gap for women is 9.5 years.

In his speech, A/Professor Owler said that in many respects the term ‘social determinants of health’ was misconstrued, because health was in fact a determinant of social and other outcomes.

He said the fact that chronic and non-communicable diseases and other preventable occurrences such as suicide, trauma and injury accounted for a major proportion of the gap in life expectancy underlined the need for greater investment in health care, particularly Aboriginal community controlled health services.

“While those with chronic disease need to be cared for, prevention, particularly in the early part of life, is the key if we are going to see a generational change in health outcomes,” A/Professor Owler said.

He said hard-earned experience showed that health was fundamental to closing the gap, as was the need to work in partnership with Indigenous communities themselves.

“There have been many examples of governments trying to address the social determinants of health – but often they have failed,” he said, referring to policies including building inappropriate housing and taking children from their families.

The AMA President said any attempt to improve Indigenous health needed to acknowledge the fundamental importance for Aboriginal and Torres Strait Islander people of their connection with the land, and understand that in many Aboriginal languages health was a concept of social and emotional wellbeing rather than a physical attribute.

He told the London conference that this was one of reasons why the AMA was a foundation member of the campaign to achieve constitutional recognition for Indigenous Australians.

“Constitutional recognition is a vital step towards making Aboriginal and Torres Strait Islander people feel historically and integrally part of the modern Australian nation,” A/Professor Owler said. “Recognising Indigenous people in the Constitution will improve their self-esteem, their wellbeing, and their physical and mental health.”

Prime Minister Tony Abbott has taken a personal interest in Indigenous affairs, concentrating responsibility for many Indigenous policy areas within the Department of Prime Minister and Cabinet and overseeing the development of the Indigenous Advancement Strategy.

Priorities for the Strategy include improving school attendance, boosting Indigenous employment and improving community safety.

A/Professor Owler said these were all worthy aims, but the Strategy overlooked the central importance of health.

“What is missing from the core of the IAS is a focus on health,” the AMA President said. “Health underpins many of these outcomes. We need to get the balance right and we, the AMA, need to ensure that health is seen as a foundation to these outcomes.”

He said that “spending on health is an investment. Investing in health must underpin our future policies to Close the Gap, and to address what is, for Australia, a prominent blight on our nation”.

Adrian Rollins

 

 

New strains force late start for flu vaccination program

Doctors and patients will for the first time have access to single-dose vaccines covering the four most common flu viruses amid concerns a mutated strain that wreaked havoc in the northern hemisphere could take hold in Australia.

The Therapeutic Goods Administration has approved nine vaccines, including, for the first time, three quadrivalent formulations, as preparations advance for the roll-out of National Seasonal Influenza Immunisation Program from 20 April.

The TGA said the vaccines approved for the program provided coverage for two new strains following expert advice about the prevalence of different types of infections in the last 12 months.

The World Health Organisation and the Australian Influenza Vaccine Committee have recommended that vaccines this year cover one existing and two new strains – the California H1N1-like virus that has been in circulation since 2010, the Switzerland H3N2-like virus and the Phuket 2013-like virus.

In addition, the quadrivalent vaccines, FluQuadri, FluQuadri Junior, and Fluarix Tetra, will cover the Brisbane 2008-like virus.

Drug company Sanofi Pasteur, which manufactures two of the quadrivalent vaccines, said they were well tolerated and provided additional protection because they covered both B strains of the influenza virus as well as the two A strains – compared with trivalent vaccines that covered both A strains but only one B strain.

The national immunisation program, which usually commences in March, had been held back a month as manufacturers have scrambled to produce sufficient stocks of the vaccines.

“The double-strain change has resulted in manufacturing delays due to the time it takes to develop, test and distribute the reagents needed to make the vaccine,” a Health Department spokesperson said. “The commencement of the program is being delayed to ensure sufficient supplies of influenza vaccine are available from at least two suppliers in order to mitigate the risk of administration of bioCSL’s Fluvax to children under five years of age.”

The AMA and other health groups expressed alarm last year over revelations that 43 infants and toddlers were injected with Fluvax in 2013 despite warnings it could trigger fever and convulsions.

The TGA has repeated its advice that Fluvax is not registered for use on children younger than five years, and that it should only be used on children between five and nine years following “careful consideration of potential benefits and risks in the individual child”.

Fluvax will be supplied with prominent warning signs and labels to remind practitioners that it should not be administered to young children.

In a stroke of good fortune, the delay in the vaccination program has coincided with a relatively quiet start to the flu season, with reports that influenza activity has so far been weaker than that experienced at the same time last year.

The Health Department and the TGA said that, despite the delay, they do not expect any flu vaccine shortages, and the Government has committed $4.5 million over the next five years to provide free flu vaccination for Indigenous children aged between six months and five years.

The Government has also renewed the contract of the Australian Sentinel Practices Research Network, based at the University of Adelaide, to undertake national surveillance of flu-like illnesses.

The network, which has been operating for more than a decade, collates information from more than 200 GPs and medical practices across the nation to provide health authorities with an early warning of developing outbreaks. Its information is used in conjunction with data from hospitals.

Adrian Rollins